公司核心产品为血管内超声（IVUS）诊断系统和血流储备分数（FFR）测量系统。公司是国内首家拥有血管 内功能学FFR及影像学IVUS产品组合的国产医疗器械公司，填补了国内市场的空白并改写了中国冠状动脉疾 病临床精准诊断完全依赖进口产品的局面。其中，FFR系统于2020年上市后即于2021年占据30.6%的国内市场 份额。截至2025年6月末，公司拥有发明专利86项，拥有14项PCT国际专利申请。 上交所在审核中关注的主要问题包括：核心产品的市场空间及对公司业绩的影响；行业政策变动是否对公司业 绩有重大不利影响，公司经营业绩是否存在下滑的风险；经销模式下收入确认的准确性；尚未盈利及大额累计 亏损是否影响持续经营能力等。 近日，上交所发布了《上交所上市审核委员会2025年第23次审议会议公告》。上交所上市审核委员会定于 2025年7月18日召开2025年第23次上市审核委员会审议会议。审议的发行人是北芯生命。这是继禾元生物之 后，2025年第二家上会采用科创板第五套标准上市的企业。 7月13日起，深化科创板改革配套业务规则已经正式实施。新上市未盈利企业自上市之日起进入科创板成长 层。 第二家即将上会 北芯生命20 ...

Group 1: New IPOs - This week, there are two new stocks available for subscription: one on the Shanghai Stock Exchange and one on the ChiNext [1][2] - The Shanghai Stock Exchange new stock, Jiyuan Group (603262), has an issue price of 10.88 yuan and a price-to-earnings ratio of 25.95 times, compared to the industry average of 15.28 times [2] - The ChiNext new stock, Shanda Electric (301609), has an issue price of 14.66 yuan and a price-to-earnings ratio of 19.57 times, with the industry average at 19.03 times [2] Group 2: Jiyuan Group Overview - Jiyuan Group specializes in the research, innovation, and industrialization of dietary nutritional supplements and is the largest global supplier of HMB raw materials [2][6] - HMB, or β-hydroxy-β-methylbutyrate, is a metabolite of the essential amino acid leucine, promoting protein synthesis and reducing breakdown, thus enhancing strength and delaying muscle fatigue [2] - The company has established long-term partnerships with major brands such as Abbott, Blackmores, and Nutramax, covering markets in China, Asia, the US, Europe, Australia, and South America [2] Group 3: Financial Performance of Jiyuan Group - From 2023 to the first quarter of 2025, Jiyuan Group achieved revenues of 892 million yuan, 1 billion yuan, and 265 million yuan, with net profits of 160 million yuan, 174 million yuan, and 43 million yuan respectively [2] Group 4: Shanda Electric Overview - Shanda Electric focuses on the research and industrialization of smart products related to power systems, with two main business segments: smart grid monitoring and renewable energy [3] - The company’s leading products include fault recording monitoring devices and transmission line fault monitoring devices [3] Group 5: Financial Performance of Shanda Electric - From 2023 to the first quarter of 2025, Shanda Electric reported revenues of 549 million yuan, 658 million yuan, and 111 million yuan, with net profits of 103 million yuan, 127 million yuan, and 17 million yuan respectively [3] Group 6: Fundraising Plans - Jiyuan Group plans to raise a total of 544 million yuan for projects including the construction of a nutritional health raw material production base and a technology innovation center [3][5] - Shanda Electric aims to raise 597 million yuan for projects related to smart grid fault analysis and production of intelligent charging piles for new energy vehicles [3][5] Group 7: North Chip Life IPO - North Chip Life is set to present its IPO on July 18, focusing on innovative medical devices for cardiovascular disease diagnosis and treatment [4] - The company’s core products include the first domestically approved high-definition IVUS diagnostic system and FFR measurement system, filling a gap in the domestic market [4][5]

2025.05. 26 本文字数：4795，阅读时长大约8分钟 作者 | 第一财经 钱童心 人工智能正在将临床诊疗方式从经验医学转变为由数据驱动。从影像识别、病理分析到手术机器人， AI的发展正在推动个性化治疗的发展，掀起一场"智能医学"的变革。 但这并不意味着我们不再需要有经验的医生，而是在AI的赋能下，更多的年轻医生利用技术也能提升 诊疗水平，整个医疗价值链也将被重塑。 AI能精准诊断冠心病吗 人工智能等新技术的飞速发展，正在悄然改变社会和人们的生活，在医学领域亦是如此，新技术为临 床诊疗和科学研究带来了新视野，也已经产生了不少突破性的成果。 "原本依赖医生经验与感觉判断的部分，在智能化与数字化的辅助下，边界也没有那么绝对了。"中国 科学院院士、复旦大学附属中山医院樊嘉教授在《在科技变革中，成为不可替代的你》一文中写道。 樊嘉表示，数字孪生医生已逐渐成为中山医院医疗团队中的重要成员——这些"数字分身"会对"生物 人医生"原型进行建模与仿真，而不仅仅是知识结构的复制和经验叠加。 他告诉第一财经记者，这些"数字医生"有些已经成形，例如"小葛"医生和"小白"医生，分别代表了中 山医院心内科葛均波院士及呼吸科白春 ...

Group 1: AI in Clinical Diagnosis - Artificial intelligence is transforming clinical diagnosis from experience-based medicine to data-driven approaches, enhancing personalized treatment [1][3] - AI technologies, such as digital twin doctors, are being integrated into medical teams, allowing for modeling and simulation of patient data to improve diagnosis and treatment [3][12] - A deep learning model for CT myocardial perfusion imaging has been developed to accurately assess myocardial ischemia, providing valuable quantitative metrics for doctors [6][7] Group 2: AI in Surgical Procedures - AI-assisted surgical robots are being utilized for remote surgeries, breaking geographical barriers and allowing for complex procedures to be performed from a distance [8][9] - The development of AI systems for pre-surgical planning is enabling surgeons to visualize and simulate operations, improving precision and outcomes [11][12] - AI is expected to play a significant role in the future of smart hospitals, enhancing patient monitoring and treatment planning through digital twin technology [13] Group 3: Ethical Considerations and Future Implications - The integration of AI in healthcare raises ethical questions, particularly regarding data security and the role of AI in decision-making processes [18][19] - Experts emphasize that AI should serve as a "super assistant" to doctors, enhancing their capabilities rather than replacing them, especially in areas requiring empathy and moral judgment [19] - The future of healthcare is envisioned as a collaboration between AI and human doctors, where AI alleviates repetitive tasks, allowing doctors to focus on patient care [19]